Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Chance Pharma Acquires China Rights for Inhaled Parkinson’s Therapy in $144 Million Deal

publication date: May 10, 2023

Hangzhou Chance Pharma entered a deal worth up to $144 million to commercialize Acorda’s inhaled therapy for Parkinson’s disease in Greater China. In the US, Inbrija is approved as an intermittent treatment for episodic motor fluctuations (OFF episodes) in adult Parkinson's disease patients who are being treated with a levodopa/dopa-decarboxylase inhibitor. Chance, which will be responsible for China regulatory approval, will make up-front and milestone payments of $11.5 million plus up to $132.5 million in sales milestones. China has the world’s largest population of patients with Parkinson’s. More details....

See our other articles on Chance.

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital